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Diarrhea is one of the top disease killers in newborns
and young infants of the developing world, yet the
research funding for vaccine development of enteric dis-
eases falls far behind the investment that has been made
in preventing diseases with lower burden to the world’s
population. Advances in this field have been delayed not
only due to poor funding, but also due to knowledge
gaps in our understanding of the gut mucosal immune
system, especially its development during the early life.
Modern biotechnology has yielded an abundance of
vaccine candidates against enteric infections. If these
candidates are to ultimately reach those in need in
developing countries, several lessons from clinical and
field research done in these settings must be considered.
These lessons include the need to develop vaccines that
can be administered without needles or sophisticated
delivery devices. These vaccines must work in the most
impoverished populations and must be able to contain
epidemics following complex emergencies. An ideal vac-
cine should prevent entry and replication of pathogens
in the gut epithelium and confer herd protection. Such
vaccine must protect all age groups at high risk and be
safe and effective in immunocompromised people.
Extensive research is being carried out to identify pro-
tective antigens, pertinent vaccination regimens includ-
ing prime-boost strategies and alternate delivery routes,
novel delivery systems, new vectors and safe adjuvants
for mucosal immunization. We have now documented
the effectiveness of an oral killed whole cholera bacteria
vaccine in children from a cholera endemic area in one
of the largest clinical efficacy trials ever conducted for
an enteric vaccine. The vaccine can be produced at
industrial scale, is affordable to the poorest, and confers
direct and community protection for at least 3 years. A
second vaccine against typhoid fever is at a late stage of
development and has been shown to be highly immuno-
genic in children. A third vaccine is at an early stage of
development and targets Shigella bacteria, the causative
agent of one of the most severe forms of diarrheal dis-
ease, bacillary dysentery. The vaccine is based on a pro-
tein antigen conserved among all species and serotypes
(>50) of Shigella co-administered with a novel mucosal
adjuvant and has already been shown to confer protec-
tion against experimental shigellosis in 3 animal models.
In partnership with PATH, the IVI is conducting a pro-
gram entailing production process development and
early clinical testing of this subunit vaccine anticipated
to commence in 2012.
Published: 10 January 2011
doi:10.1186/1753-6561-5-S1-L2
Cite this article as: Czerkinsky: Enteric vaccines for the developing
world: challenges and prospects. BMC Proceedings 2011 5(Suppl 1):L2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit International Vaccine Institute, Seoul, Korea
Czerkinsky BMC Proceedings 2011, 5(Suppl 1):L2
http://www.biomedcentral.com/1753-6561/5/S1/L2
© 2011 Czerkinsky; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.